Navigation Links
Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
Date:1/14/2008

CARMIEL, Israel, Jan. 14 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that it has signed a lease agreement for the expansion of its manufacturing and research facility. The expanded space, located in the Company's facility in Carmiel, Israel, will provide the Company with approximately three times its current manufacturing space in anticipation of the potential commercialization of the Company's lead product candidate, prGCD, a therapeutic protein for the treatment of Gaucher disease.

The term of the lease agreement is 7.5 years with options to extend the life of the lease for up to 15 additional years. The Company intends to use the expanded facility for the manufacture of prGCD. The Company expects the facility to continue enjoying the Approved Enterprise status originally granted to the facility by the Investment Center of the Israeli Ministry of Industry, Trade and Labor. Under Israel's Law for the Encouragement of Capital Investments, 1959, the income from an Approved Enterprise will be exempt from taxation in Israel for a period of 10 years, commencing with the year in which taxable income is first generated from the Approved Enterprise.

Commenting on the expansion of the manufacturing facility, Yossi Maimon, the Company's Chief Financial Officer, said, "In light of the progress we have made to date in our prGCD program, we determined that we should commence the expansion of our current facility. Our expanded facility will provide us with the space and capacity required to bring prGCD to market and meet the anticipated demand for the drug following its anticipated approval by the United States Food and Drug Administration, while continuing to advance the research of the additiona
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
2. Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference
3. Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock
4. Protalix BioTherapeutics Announces Public Offering of Common Stock
5. Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference
6. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
7. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
8. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
9. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
10. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
11. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud ... partially hydrolyzed gluten in foods, has been accepted by AOAC International as Official ... Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific ...
(Date:7/30/2015)... CAMBRIDGE, Mass. , July 30, 2015 /PRNewswire/ ... software solutions for the interpretation and analysis of ... Matthew Fischer has joined the company ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... astounding capabilities to integrate, interpret, analyze and explore ...
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)... 2015   Senomyx , Inc. (NASDAQ: SNMX ... to discover, develop, and commercialize novel flavor ingredients for ... financial results for the second quarter 2015. ... remain on track to achieve our commercial and financial ... of the Company. "Since our last quarterly earnings report, ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... assay effectively identifies melanoma, LA JOLLA, Calif., ... diagnostics for the early detection of,melanoma and other ... Cancer Research on its non-invasive assay that distinguishes ... Genomic Assay for,the Detection of Melanoma in Suspicious ...
... CEDAR KNOLLS, N.J., April 15 Emisphere,Technologies, Inc. ... will host its,Annual Stockholders Meeting on Thursday, May ... Two Whippany Road, Morristown, New Jersey. The,meeting will ... TECHNOLOGIES, INC., Emisphere Technologies, Inc. is a ...
... -ARIUS report new data and program updates on cancer stem cell ... ... April 15 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a biotechnology company ... it will be presenting new,findings and program updates related to its ...
Cached Biology Technology:DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR 2Emisphere Technologies To Hold Annual Stockholders Meeting on May 8, 2008 2ARIUS presents new findings for anti-cancer antibody programs at AACR 2ARIUS presents new findings for anti-cancer antibody programs at AACR 3ARIUS presents new findings for anti-cancer antibody programs at AACR 4ARIUS presents new findings for anti-cancer antibody programs at AACR 5
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
(Date:7/20/2015)... -- Acuity Market Intelligence,s latest research "The Global Biometrics ... Privacy" forecasts that between 2014 and 2020 nearly ... to smart mobile devices by 2.2 billion mobile ... to generate more than $67.9 billion in total ...    "Biometrics is at the center ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... Baltimore, MD The human genome shares several peculiarities with the ... Our genetic blueprint contains numerous entities known as transposons, or ... to place on the chromosomes within a cell. ... transposon elements and the decaying remains of former transposons that ...
... meeting of the American Fisheries Society will take place in ... conference is "New Frontiers in Fisheries Management and Ecology: Leading ... http://afs2011.org/ All talks will be at the ... Eat but don,t get eaten: after restoration, young salmon better ...
... discovery by the University of Colorado Boulder and the ... "power plants" within cells known as mitochondria has implications ... and conditions due to mitochondrial defects. Led by ... collaboration with the UC-Davis team led by Professor Jodi ...
Cached Biology News:A 'jumping gene's' preferred targets may influence genome evolution 2A 'jumping gene's' preferred targets may influence genome evolution 3USGS research frontiers on fish at the American Fisheries Society Conference 2USGS research frontiers on fish at the American Fisheries Society Conference 3USGS research frontiers on fish at the American Fisheries Society Conference 4USGS research frontiers on fish at the American Fisheries Society Conference 5USGS research frontiers on fish at the American Fisheries Society Conference 6USGS research frontiers on fish at the American Fisheries Society Conference 7New cellular surprise may help scientists better understand human mitochondrial diseases 2
Request Info...
... CultureWell cell culture systems provide ... cultured cells for staining and ... silicone gaskets preassembled with standard ... plates. The entire system is ...
... The Captivate magnetic separator ... be used in conjunction with ... C-21474, C-21476) or other magnetic ... most 96-well microplates. Cell Biology ...
ANTI L-DOPA...
Biology Products: